The board of directors for Thoratec (NSDQ:THOR) authorized a $200 million repurchase program for shares of the company’s common stock.
Thoratec Corp.
Thoratec slides after NEJM reports increased blood clot rates
Listen to Thoratec’s Q3 earnings call
Thoratec gains on Q3 earnings beat
Thoratec ticks up, HeartWare slides on new Medicare rules for heart pump implants
The Centers for Medicare & Medicaid Services issued new proposed rules for left ventricular assist devices, the heart pump implants designed to help patients with end-stage heart disease either make the bridge to transplant or to assist their hearts until the end of life – so-called “destination therapy.”
Thoratec soars on Q2 earnings
Thoratec acquires Terumo’s DuraHeart II for up to $44M
Thoratec announces FDA approval of HeartMate II pocket controller
Thoratec (NSDQ:THOR) said it got the go-ahead from the FDA to market its HeartMate II pocket controller.
The pocket controller is designed to support the active lifestyles of patients with HeartMate II left ventricular assist devices, the Pleasanton, Calif.-based medical device company stated in a press release.
Thoratec shares drop 10% on a harsh 1st quarter report
Thoratec touts 1st human use for catheter-based HeartMate PHP heart pump
Thoratec (NSDQ:THOR) touted the 1st human use of its HeartMate PHP device as a "milestone case" for the heart pump technology.
Dr. Adrian Ebner at Sanatorio Italiano in Asuncion, Paraguay, used HeartMate PHP to stabilize a patient for an hour on the operating table during a percutaneous coronary procedure. Two other patients were subsequently treated with the catheter-based heart pump.